Highlights: Australian Q3 FY23 sales of A$577 k North American Q3 FY23 Travelan® sales of A$298 k Global Q3 YTD FY23 sales of A$1.46 M represent an increase of 239% compared with the. | April 6, 2023
Highlights: First participants enrolled in USU Travelan Clinical Trial Field Study157 participants successfully randomized into the Clinical StudyPlans in place to enrol in 1302 healthy volunteers in. | January 18, 2023
Immuron Update on IMM-124E SARS-CoV-2 Research Melbourne, Australia, August 19, 2022: Immuron Limited , a commercial and clinical-stage biopharmaceutical company with a. | August 19, 2022
Key Highlights: North American Travelan® sales up by 185% YoY in Q3 FY22Global sales up 216% YoY in Q3 FY22.YTD March 31, FY22 worldwide Travelan® sales reached AU $392K, increasing. | April 27, 2022
MELBOURNE, Australia, Jan. 13, 2022 Immuron Limited , an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment. | January 13, 2022